Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)The purpose of this study is to describe the long-term safety of dupilumab in treatment of patients with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551). Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 12 and above
Care during COVID-19 surveyThe purpose of this study is to understand how patients with asthma and COPD have been affected by the changes to the health care system as a result of the COVID-19 pandemic. To complete the survey, visit: https:/Recruiting Principal Investigator Christopher CarlstenBody Locations and Systems Asthma, COPDArea VancouverAge 18 and above
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent AsthmaThe objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066 as compared to placebo over a 24-week treatment period in severe asthma patients. The primary endpoint is time to first asthma worsening during the planned 24 week treatment period for active vs.Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18-75
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)Primary Objective: Evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma study. Secondary Objectives:Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 12 and above
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics (ARIA)This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18-65
Evaluating the Safety and Efficacy of Benralizumab to Treat Patients With Severe Uncontrolled Asthma (ANDHI)The purpose of this study is to investigate the safety and efficacy of a study drug, benralizumab, in comparison to placebo in patients with severe asthma that is not well controlled by their current asthma medications. Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18-75
Undiagnosed COPD and Asthma Population Study (UCAP)The purpose of this study is to determine whether early treatment of undiagnosed lung conditions of asthma or COPD will improve patient's overall health. Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems Asthma, COPDArea VancouverAge 18 and above
Severe Asthma Research RegistryThe purpose of the registry is to gather detailed information on the nature and treatment of as many people with moderate to severe asthma as possible, and to better understand why exacerbations (worsening) of asthma develop. Medical research using data from the registry will give us a better unRecruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 19 and above
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)The purpose of this study is to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma. Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18-75
GB001 in Adult Subjects With Moderate to Severe AsthmaThe purpose of this study is to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment. Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18-74
A Randomized, Controlled, Clinical Trial to Address the Burden of Undiagnosed Airflow Obstruction in Canadian AdultsThe purpose of this study is to use targeted casefinding to find people with undiagnosed asthma and COPD in Canadian communities. Recruiting Principal Investigator Mark FitzGeraldBody Locations and Systems COPD, AsthmaArea VancouverAge 18 and above
Asthma Self-management Via Application of Telehealth (asthma)The disease being studied is asthma.Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 19-85
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled…The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020. Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 12-75
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma (SYGMA1)The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma.Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 12-130
Longitudinal Cohort Study in Participants With Severe Asthma to Assess BiomarkersProspective, single-arm, longitudinal, international, multicentre study in a real-world cohort of adult severe asthma participants being conducted to assess the relationships between asthma biomarkers and asthma-related health-outcomes for a period of 52 weeks.Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18 and above
Evaluation of Dupilumab in Patients With Persistent AsthmaPrimary Objective: To evaluate the efficacy of dupilumab (SAR231893 [REGN668]) in patients with persistent asthma. Secondary Objectives:Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 12 and above
Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids (MESOS)A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled Corticosteroid. Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18-75
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severeClosed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 12 and above
A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic AsthmaThis is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study.Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 18-60
A Study to Evaluate the Safety and Efficacy of Tezepelumab in Adults with Severe Uncontrolled AsthmaThe purpose of the study is to see if Tezepelumab is effective in treating sever asthma and whether is causes any side effects. Closed for Recruitment Principal Investigator Mark FitzGeraldBody Locations and Systems AsthmaArea VancouverAge 19-80
